4
Changes in Ownership
Spyre Therapeutics, Inc. Filed Acc 0001140361-17-045129
Chief Financial Officer and VP bought 25,959 shares at an average $4.48 ($116,223)
From the SEC's structured data for this filing
Trades in this filing
York Charles N II · Chief Financial Officer and VP
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2016-08-15 | Purchase : show line 1 in the form | +2,000 | $3.99 | $7,974 | 10,828 | D |
| 2017-02-15 | Purchase : show line 2 in the form | +2,000 | $4.28 | $8,568 | 12,828 | D |
| 2017-08-15 | Purchase : show line 3 in the form | +1,959 | $2.52 | $4,929 | 14,787 | D |
| 2017-12-01 | Purchase : show line 4 in the form | +6,500 | $4.59 | $29,855 | 21,287 | D |
| 2017-12-04 | Purchase : show line 5 in the form | +3,259 | $4.97 | $16,197 | 24,546 | D |
| 2017-12-05 | Purchase : show line 6 in the form | +10,241 | $4.76 | $48,700 | 34,787 | D |
| Open-market purchases · 25,959 sh · avg $4.48 · $116,223 | ||||||
Loading xslF345X03/doc1.xml…